PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 107 filers reported holding PMV PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,587,320 | -23.1% | 2,375,785 | -21.6% | 0.31% | -14.7% |
| Q2 2023 | $18,964,989 | +32.6% | 3,029,551 | +1.0% | 0.36% | +21.1% |
| Q1 2023 | $14,305,697 | -62.3% | 2,999,098 | -31.2% | 0.30% | -61.5% |
| Q4 2022 | $37,905,204 | -26.9% | 4,356,920 | 0.0% | 0.77% | -35.2% |
| Q3 2022 | $51,847,000 | -17.2% | 4,356,920 | -0.9% | 1.20% | -26.1% |
| Q2 2022 | $62,638,000 | -22.3% | 4,395,677 | +13.5% | 1.62% | -3.1% |
| Q1 2022 | $80,618,000 | +17.1% | 3,872,154 | +29.9% | 1.67% | +65.9% |
| Q4 2021 | $68,860,000 | +185.3% | 2,980,960 | +268.1% | 1.01% | +176.4% |
| Q3 2021 | $24,134,000 | +45.9% | 809,863 | +67.3% | 0.36% | +45.6% |
| Q2 2021 | $16,538,000 | +3.9% | 484,133 | 0.0% | 0.25% | +0.4% |
| Q1 2021 | $15,923,000 | -48.3% | 484,133 | -3.3% | 0.25% | -51.8% |
| Q4 2020 | $30,809,000 | +73.6% | 500,882 | +0.2% | 0.52% | +21.1% |
| Q3 2020 | $17,750,000 | – | 500,000 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERWEST VENTURE MANAGEMENT CO | 1,614,911 | $23,012,000 | 42.78% |
| Euclidean Capital LLC | 2,336,909 | $33,301,000 | 28.32% |
| OUP Management Co., LLC | 989,232 | $14,097,000 | 19.40% |
| Nextech Invest Ltd. | 1,385,807 | $19,748,000 | 6.66% |
| Boxer Capital, LLC | 3,498,636 | $49,856,000 | 3.16% |
| PERSONAL CFO SOLUTIONS, LLC | 550,342 | $7,842,000 | 1.84% |
| Orbimed Advisors | 6,563,077 | $93,524,000 | 1.70% |
| RTW INVESTMENTS, LP | 4,395,677 | $62,638,000 | 1.62% |
| ACUTA CAPITAL PARTNERS, LLC | 152,500 | $2,173,000 | 1.21% |
| Avoro Capital Advisors LLC | 3,100,000 | $44,175,000 | 0.87% |